Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
NCT ID: NCT04830397
Last Updated: 2025-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
84 participants
INTERVENTIONAL
2021-03-31
2022-02-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
NCT04857827
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
NCT06030193
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
NCT04947124
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
NCT06016972
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
NCT05495269
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QLS-101 0.5%
QLS-101
Ophthalmic solution 1x daily
QLS-101 1%
QLS-101
Ophthalmic solution 1x daily
QLS-101 2%
QLS-101
Ophthalmic solution 1x daily
Timolol Maleate 0.5% preservative free ophthalmic solution
Timolol Maleate
Ophthalmic solution 1x daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QLS-101
Ophthalmic solution 1x daily
Timolol Maleate
Ophthalmic solution 1x daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing to give informed consent
3. Ability to washout from current intraocular pressure lowering medications -
Exclusion Criteria
2. Previous glaucoma intraocular or laser surgery
3. Refractive surgery
4. Ocular infection or inflammation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qlaris Bio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dixon Eye Care
Albany, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Company website, pipeline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QC-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.